[Efficacy of Recombinant Thrombomodulin for Sepsis-Associated Disseminated Intravascular Coagulation Caused by Urinary Tract Infections].

Akira Tachibana, Kota Iida, Yoshitaka Itami, Masaya Hashimura, Yuta Toyoshima, Yukinari Hosokawa, Kiyohide Fujimoto
{"title":"[Efficacy of Recombinant Thrombomodulin for Sepsis-Associated Disseminated Intravascular Coagulation Caused by Urinary Tract Infections].","authors":"Akira Tachibana, Kota Iida, Yoshitaka Itami, Masaya Hashimura, Yuta Toyoshima, Yukinari Hosokawa, Kiyohide Fujimoto","doi":"10.14989/ActaUrolJap_69_11_309","DOIUrl":null,"url":null,"abstract":"<p><p>Severe urinary tract infections occasionally cause sepsis and disseminated intravascular coagulation (DIC). We examined the efficacy of recombinant thrombomodulin (rTM) for treating DIC caused by urosepsis. We enrolled 40 patients who were diagnosed with DIC caused by urosepsis at our hospital between April 2018 and May 2022. Twenty-six patients were treated with rTM (rTM group), while 14 patients did not receive rTM (non-rTM group). The DIC score before treatment in the rTM group was significantly higher than that in the non-rTM group (P<0.01). There was no significant difference in disease-specific survival between the two groups. There was a significant improvement in DIC scores on days 1-3 after administering rTM. However, the duration of DIC in the rTM group was significantly longer than that in the non-rTM group (P=0.038). The administration of rTM may have benefits in patients with DIC caused by urosepsis.</p>","PeriodicalId":39291,"journal":{"name":"Acta Urologica Japonica","volume":"69 11","pages":"309-314"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Urologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14989/ActaUrolJap_69_11_309","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Severe urinary tract infections occasionally cause sepsis and disseminated intravascular coagulation (DIC). We examined the efficacy of recombinant thrombomodulin (rTM) for treating DIC caused by urosepsis. We enrolled 40 patients who were diagnosed with DIC caused by urosepsis at our hospital between April 2018 and May 2022. Twenty-six patients were treated with rTM (rTM group), while 14 patients did not receive rTM (non-rTM group). The DIC score before treatment in the rTM group was significantly higher than that in the non-rTM group (P<0.01). There was no significant difference in disease-specific survival between the two groups. There was a significant improvement in DIC scores on days 1-3 after administering rTM. However, the duration of DIC in the rTM group was significantly longer than that in the non-rTM group (P=0.038). The administration of rTM may have benefits in patients with DIC caused by urosepsis.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重组凝血调节蛋白治疗尿路感染所致脓毒症相关性弥散性血管内凝血的疗效研究。
严重的尿路感染偶尔会引起脓毒症和弥散性血管内凝血(DIC)。我们观察了重组血栓调节素(rTM)治疗尿脓毒症引起的DIC的疗效。我们纳入了2018年4月至2022年5月在我院诊断为尿脓毒症引起的DIC的40例患者。26例患者接受rTM治疗(rTM组),14例患者未接受rTM治疗(非rTM组)。rTM组治疗前DIC评分显著高于非rTM组(P<0.01)。两组患者的疾病特异性生存率无显著差异。给予rTM后第1-3天DIC评分有显著改善。但rTM组DIC持续时间明显长于非rTM组(P=0.038)。对尿脓毒症引起的DIC患者给予rTM可能有益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Urologica Japonica
Acta Urologica Japonica Medicine-Medicine (all)
CiteScore
0.20
自引率
0.00%
发文量
74
期刊最新文献
[The Case of Solitary Adrenal Metastasis of Urothelial Carcinoma]. [The Introduction of Pubic Hair into the Bladder : A Possibility of an Alternate Mechanism]. [A Case of Metastatic Testicular Cancer after Kidney Transplantation in which Complete Remission was Achieved]. [A Case of Pelvic Arteriovenous Malformation in a Male with Massive Bladder Bleeding which Caused Severe Hemorrhagic Hypovolemic Shock]. [Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1